Featured Research

from universities, journals, and other organizations

A giant 'little step' in cancer treatment opening up new therapeutic horizons

Date:
February 27, 2012
Source:
Vall d´Hebron Institute of Oncology (VHIO)
Summary:
A new study heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options. The data demonstrate that by combining two drugs that had already been used on a patient in the past but had stopped working, they boost each other’s efficacy and at the same time manage to break down the patient’s resistance to each of them individually, presenting a third potential treatment option for clinically advanced metastatic tumors. While this may not initially appear to be an innovation, given that combined treatments are used in cancer as a matter of course, it actually represents a radical change in the use of the existing therapeutic weaponry, an extremely practical solution and a source of hope for many patients.

A study headed up by the Vall d’Hebron Institute of Oncology (VHIO) heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options. The data, published today in the Journal of Clinical Oncology, demonstrate that by combining two drugs that had already been used on a patient in the past but had stopped working, they boost each other’s efficacy and at the same time manage to break down the patient’s resistance to each of them individually, presenting a third potential treatment option for clinically advanced metastatic tumours. While this may not initially appear to be an innovation, given that combined treatments are used in cancer as a matter of course, it actually represents a radical change in the use of the existing therapeutic weaponry, an extremely practical solution and a source of hope for many patients.

“The novelty factor does not lie in the combination itself, but in the combination of two drugs that had already been administered in the past and had each failed,” explained Dr Javier Cortés, the Head of the Breast Cancer Programme at the VHIO and main author of this work. This not only offers new alternatives for patients with advanced tumours –the most important aspect – but also opens up a parallel dimension of new therapeutic options to the existing treatments, given that it offers numerous combinations between existing pharmacological treatments that not only boost each other but also counteract patients’ resistance to them.

“The study focused on HER2 positive breast cancer, although the concept could be applied to the treatment of other tumours”, continued Dr Cortés. Breast tumours occur most frequently in Western women. In Spain alone, some 24,000 new cases are diagnosed each year, and it is calculated that one in every eight or nine women in this country will suffer from breast cancer. Although the many advances over recent years in screening, early diagnosis and treatments have dramatically reduced mortality from this disease, there are still breast tumours whose biological characteristics make them more aggressive.

Around 15% of breast tumours are HER2 positive and fall into this category. Moreover, they tend to affect younger women. In spite of the fact that this group has benefited tremendously from specific biological therapies targeted at this subtype (monoclonal antibodies), many tumours continue to advance and metastasize. “When a patient with this breast cancer subtype stops responding to the initial drug and the disease progresses, a second drug is administered. It may be that the response to these two treatments is negligible or there may even be no response at all and the tumour continues to grow.If we then treat the patients with the two drugs in combination, even though they ceased to function individually, what we have found is that almost 50% of the tumours responded to this combination and did so very positively, showing a clear improvement or keeping the disease stable for a considerable period of time”, concluded Dr Cortés.

In the fight against cancer, the combination of treatments is highly common practice. However, the concept described is different: it is not about seeing the results of combining drug A with drug B, but, when A fails to work, B is administered, and if this also fails we return to the starting point and initiate treatment with a combination of the two (A + B).

This strategy could offer an unprecedented key to multiplying treatment options. In the specific case of this study, we administered trastuzumab (the first-choice treatment for HER2 positive breast cancer); when the tumour continued growing we used pertuzumab (currently pending approval) and when the cancer continued to progress we administered the two together. “The results were very positive and highly informative for new studies,” said Dr Cortés.


Story Source:

The above story is based on materials provided by Vall d´Hebron Institute of Oncology (VHIO). Note: Materials may be edited for content and length.


Journal Reference:

  1. Javier Corte´s, Pierre Fumoleau, Giulia Valeria Bianchi, Teresa M. Petrella, Karen Gelmon, Xavier Pivot, Shailendra Verma, Joan Albanell, Pierfranco Conte, Ana Lluch, Stefania Salvagni, Veronique Servent, Luca Gianni, Maurizio Scaltriti, Graham A. Ross, Joanna Dixon, Tania Szado, and Jose´ Baselga. Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 2012

Cite This Page:

Vall d´Hebron Institute of Oncology (VHIO). "A giant 'little step' in cancer treatment opening up new therapeutic horizons." ScienceDaily. ScienceDaily, 27 February 2012. <www.sciencedaily.com/releases/2012/02/120227162603.htm>.
Vall d´Hebron Institute of Oncology (VHIO). (2012, February 27). A giant 'little step' in cancer treatment opening up new therapeutic horizons. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2012/02/120227162603.htm
Vall d´Hebron Institute of Oncology (VHIO). "A giant 'little step' in cancer treatment opening up new therapeutic horizons." ScienceDaily. www.sciencedaily.com/releases/2012/02/120227162603.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins